Department of Clinical Pharmacy and Biopharmacy, Faculty of Pharmacy, College of Medicine Campus, Idi-Araba, PMB 12003 Surulere, Lagos, Nigeria
Suleiman, I.A., Department of Clinical Pharmacy and Biopharmacy, Faculty of Pharmacy, College of Medicine Campus, Idi-Araba, PMB 12003 Surulere, Lagos, Nigeria; Tayo, F., Department of Clinical Pharmacy and Biopharmacy, Faculty of Pharmacy, College of Medicine Campus, Idi-Araba, PMB 12003 Surulere, Lagos, Nigeria
Purpose: To carry out economic evaluation of antibacterial usage for Ear, Nose and Throat infections in a tertiary health care facility in Nigeria. Methods: Antibacterial utilisation evaluation was carried out retrospectively over one year period by reviewing 122 case notes containing 182 prescriptions of patient with Ear Nose and Throat infections. Relevant data including demographics, diagnosis, prescribed drugs, dosages, were extracted and the associated costs analysed. Results: Highest prevalent rate of Ear, Nose and Throat infections occurred in children under 10 years of age (59.3%) with otitis media predominating (45.0%). Average antibacterial cost per case was N1971.37 (US$15.16). Penicillins were the most frequently prescribed (35.5%) at a cost of N89,468.00 (US$688.22) representing 24.9% of the total antibacterial cost. Cephalosporins were used at a rate of 12.1% with a percentage total antibacterial cost of 48.4% (N173,554.00, US$1335.03). Conclusion: The average cost of antibacterial agents to patients studied is high. This call for prudent use of these agents which should be evidence based and closely monitored. © Poracom Academic Publishers. All rights reserved.
amikacin; aminoglycoside antibiotic agent; amoxicillin; amoxicillin plus clavulanic acid; ampicillin; ampicillin plus cloxacillin; antiinfective agent; ceftazidime; ceftriaxone; cefuroxime; cephalosporin derivative; ciprofloxacin; cloxacillin; cotrimoxazole; erythromycin; gentamicin; imidazole derivative; macrolide; metronidazole; penicillin derivative; quinoline derived antiinfective agent; roxithromycin; sulfonamide; acute otitis media; adolescent; adult; age distribution; article; bronchopneumonia; child; chronic suppurative otitis media; controlled study; demography; drug choice; drug cost; drug monitoring; drug use; ear infection; economic evaluation; evidence based medicine; female; health care cost; high risk population; human; infant; infection rate; major clinical study; male; newborn; Nigeria; nose infection; otitis media; pharyngitis; preschool child; prescription; prevalence; retrospective study; school child; teaching hospital; tertiary health care; tonsillitis